DESIGNED FOR The treatment of psoriasis symptoms: plaques, scales, itching, redness.
ADULTS FILM-FORMING CREAM TEXTURE Protects the skin, does not leave greasiness and does not stick, allowing you to dress immediately.
DERMATOLOGICALLY TESTED On patients with psoriasis plaques.
[CHILDREN FROM 3 YEARS OLD, ADULTS] Suitable for pregnant and breastfeeding women.
[COOL TEXTURE, SOFT FINISH] Its cool texture combined with panthenol soothes the feeling of tightness and itching. Enriched with plant oils and butters, this lotion applies easily and wraps the skin without sticking. [DISCREET FRAGRANCE]
[NATURAL FORMULA] 85% ingredients of natural origin.
IN 14 DAYS
• -27% scales
AFTER 30 DAYS
• -23% redness
• +19% improvement of the plaque (total PSI score)
• 96% of patients stated that the film-forming texture spread easily
1- Mammone, T., Gan, D., Fthenakis, C.; Marenus, K. The Effect of N-Acetyl-Glucosamine on Stratum Corneum Dequamation and Water Content in Human Skin. J. Cosmet. Sci. 2009, 60, 423–428.
2- Multicenter (inactive center 1), randomized, double-blind, placebo-controlled clinical study on 30 patients with 2 psoriasis plaques (≈ 20 cm², at least 15 cm apart), in two separate phases with application of XERIAL DM Psoriasis or placebo twice daily on the psoriasis plaques for 30 days for phase 1 and for 28 days for phase 2 separately with treatment with calcipotriol and betamethasone (dermocorticosteroid). Clinical evaluation report dated 09/11/2021 no. 03-DM-2018 - ID-RCB number 2018-A03297-48. Evaluation of total PSI score and individual scores of scaling and roughness at 14 and 30 days (phase 1): PSI: n=30, mean (D0) = 7.50±1.22, mean (D14) = 6.10±1.75 (p<0.001), significant difference versus placebo, Scaling n=30, mean (D0) = 2.57±0.61, mean (D14): 1.87±0.90 (p<0.001), significant difference versus placebo. Redness n=30, mean (D0) = 2.60±0.50, mean (D30): 2.00±0.79 (p <0.001), significant difference versus placebo. Tolerance results: 42.4% of patients experienced a total of 24 mild to moderate adverse events, of which 13 were possibly related to the study products: 9 related to XERIAL DM PSORIASIS and 4 related to PLACEBO. These adverse events were: stinging (9%), itching (15%) and burning sensation (3%). All related adverse events were local and resolved before study completion.
3- Multicenter (inactive center 1), randomized, double-blind, placebo-controlled clinical study on 30 patients with 2 psoriasis plaques (≈ 20 cm², at least 15 cm apart), in two separate phases with application of XERIAL DM Psoriasis or placebo twice daily on the psoriasis plaques for 30 days for phase 1 and for 28 days for phase 2 separately with treatment with calcipotriol and betamethasone (dermocorticosteroid). Clinical evaluation report dated 09/11/2021 no. 03-DM-2018 - ID-RCB number 2018-A03297-48. 7-day self-assessment (phase 2). 4- France Psoriasis.
[RECYCLABILITY AND SORTING] Environmental properties and features: fully recyclable packaging. Contains at least 32% recycled material. Sorting instructions may vary locally.